MNKD
MannKind Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow -3.7% ·
net new positions +8.3%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | 0 | 123.03M | $523.50M | +9 | −9 |
| Q1 2026 | 95 | -6 | 143.26M | $351.80M | +6 | −12 |
| Q4 2025 | 99 | +3 | 133.27M | $755.65M | +3 | — |
| Q3 2025 | 17 | -2 | 89.45M | $480.37M | +1 | −3 |
| Q2 2025 | 16 | 0 | 83.27M | $311.43M | — | — |
| Q1 2025 | 13 | 0 | 35.19M | $177.04M | — | — |
| Q4 2024 | 13 | 0 | 35.66M | $229.30M | — | — |
| Q3 2024 | 12 | +1 | 19.40M | $122.05M | +1 | — |
| Q2 2024 | 11 | — | 20.14M | $105.14M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 6.34M | +0.4% | $39.88M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 6.34M | +0.4% | $39.88M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 3.47M | +20.3% | $21.83M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 3.47M | +20.3% | $21.83M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 3.04M | +7.6% | $19.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.65M | -65.2% | $10.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 1.30M | New | $8.18M | 0.0% | New | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.13M | -33.6% | $7.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 1.13M | -33.6% | $7.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 865.29K | +11.0% | $5.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 865.29K | +11.0% | $5.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 865.29K | +11.0% | $5.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 865.29K | +11.0% | $5.44M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 711.81K | +18.8% | $4.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 711.81K | +18.8% | $4.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 651.54K | +5012.2% | $4.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 156.20K | -18.1% | $983,000 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 43.59K | +2.0% | $274,200 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 43.59K | +2.0% | $274,200 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 43.35K | +1.3% | $272,665 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $8.18M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 250 holders, 176.45M shares, $430.71M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 39.05K sh · $158,547
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology